(Q44831239)

6 December 2017

title

Aripirazole-olanzapine combination for treatment of schizophrenia (English)

1 reference

6 December 2017

1 reference

Harpreet S Duggal

1

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Canadian Journal of Psychiatry

6 December 2017

published in

1 reference

6 December 2017

volume

49

1 reference

6 December 2017

issue

2

1 reference

6 December 2017

page(s)

151

1 reference

Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900213

10.1177/070674370404900213

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference